Disease Category Listing (102): Multiple Sclerosis

Clinical Trials: Multiple Sclerosis

Alabama

Birmingham; Research Center
Investigational Oral Medication for RRMS

Birmingham; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Cullman; Research Center
Investigational Oral Medication for RRMS

Cullman; North Central Neurology Associates, P.C.
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Huntsville; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Arizona

Gilbert; Research Center
Investigational Oral Medication for RRMS

Pheonix; Neuro-Immunology Program
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Phoenix; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Phoenix; Research Center
Investigational Oral Medication for RRMS

Phoenix; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Tucson; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Tucson; Northwest NeuroSpecialists
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Tucson; Northwest NeuroSpecialists, PLLC
Clinical Research Study Available for People Diagnosed with Multiple Sclerosis

Tucson; Northwest NeuroSpecialists, PLLC
Multiple Sclerosis Study

California

Berkeley; The REDI of Alta Bates Summit Medical Center
A research study for patients with symptoms of overactive bladder.

Berkeley; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Downey; Los Amigos Research and Education, Environmental Health Services
A research study for patients with symptoms of overactive bladder.

Fresno; Urology Associates of Central California [*]
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

La Jolla; Coordinated Clinical Research (La Jolla, CA)
Have you been diagnosed with Multiple Sclerosis? A clinical research study for Relapsing-Remitting MS is underway in your area.

La Jolla; Research Center
Investigational Oral Medication for RRMS

Laguna Hills; South Orange County Medical Research Center
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Loma Linda; Research Center
Investigational Oral Medication for RRMS

Long Beach; Atlantic Urology
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Pasadena; Research Center
Investigational Oral Medication for RRMS

Pasadena; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Sacramento; Research Center
Investigational Oral Medication for RRMS

Sacramento; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

San Francisco; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

San Francisco; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Colorado

Boulder; Research Center
Investigational Oral Medication for RRMS

Boulder; Alpine Clinical Research Center
Quality of Life study for patients with relapsing forms of Multiple Sclerosis who are transitioning from Rebif to Rebif-New Formulation

Centennial; 1st International Clinical Research Center
Do you have Relapsing Remitting Multiple Sclerosis?

Colorado Springs; Research Center
Investigational Oral Medication for RRMS

Denver; Urology Associates, PC
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Denver; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Fort Collins; Research Center
Investigational Oral Medication for RRMS

Springs; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Connecticut

Fairfield; Associated Neurologists of Southern Connecticut
A research study for patients with symptoms of overactive bladder

Middlebury; Connecticut Clinical Research Center
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

New Haven; Research Center
Investigational Oral Medication for RRMS

New Haven; Yale Center for MS Treatment and Research
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Pawcatuck; CNS Research of CT, Inc.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Salisbury; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Florida

Bradenton; Bradenton Research Center
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Bradenton; Bradenton Research Center
A research study for patients with symptoms of overactive bladder

Bradenton; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bradenton; Bradenton Research
Bradenton Neurology, Inc. is participating in a nationwide research study for individuals who have been diagnosed with Multiple Sclerosis.

Lighthouse Point; Research Center
Investigational Oral Medication for RRMS

Maitland; Research Center
Investigational Oral Medication for RRMS

Melbourne; Research Center
Investigational Oral Medication for RRMS

Melbourne; Melbourne Internal Medicine Associates (MIMA)
A research study for patients with symptoms of overactive bladder

Miami; University of Miami, Department of Neurology
A research study for patients with symptoms of overactive bladder.

Miami; Research Center
Investigational Oral Medication for RRMS

Naples; Research Center
Investigational Oral Medication for RRMS

Orlando; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Pompano Beach; Research Center
Investigational Oral Medication for RRMS

Saint Petersburg; Research Center
Investigational Oral Medication for RRMS

Sarasota; Florida Urology Specialists
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Sarasota; Research Center
Investigational Oral Medication for RRMS

Sarasota; The Roskamp Institute, Clinical Trials Division
Phase III study for patients with Relapsing remitting Multiple Sclerosis

Sarasota; The Roskamp Institute, Clinical Trials Division
Phase III study comparing different doses of study drug with placebo for Relapsing Remitting Multiple Sclerosis (RRMS)

Sarasota; The Roskamp Institute, Clinical Trials Division
Do you or a loved one have relapsing remitting multiple sclerosis?

Sarasota; Lovelace Scientific Resources - Sarasota
Multiple Sclerosis

Tallahassee; Research Center
Investigational Oral Medication for RRMS

Tampa; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Vero Beach; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vero Beach; Research Center
Investigational Oral Medication for RRMS

Georgia

Atlanta; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Atlanta; Research Center
Investigational Oral Medication for RRMS

Atlanta; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Atlanta; MS Center of Atlanta
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Augusta; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Idaho

Meridian; Research Center
Investigational Oral Medication for RRMS

Illinois

Chicago; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Evanston; Research Center
Investigational Oral Medication for RRMS

Maywood; Research Center
Investigational Oral Medication for RRMS

Northbrook; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Palos Heights; Research Center
Investigational Oral Medication for RRMS

Peoria; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Indiana

Fort Wayne; Research Center
Investigational Oral Medication for RRMS

Ft. Wayne; Fort Wayne Neurological Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Indianapolis; Research Center
Investigational Oral Medication for RRMS

Indianapolis; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Indianapolis; University of Indiana
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Iowa

Des Moines; Research Center
Investigational Oral Medication for RRMS

Kansas

Kansas City; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kansas City; Research Center
Investigational Oral Medication for RRMS

Kansas City; Landon Center / Neurology
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Kansas City; University of Kansas Medical Center
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Lenexa; MidAmerica Neuroscience Institute
Relapsing forms of Multiple Sclerosis study to evaluate the safety and tolerability of two doses of an oral study drug over 24 weeks (study 7)

Lenexa; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Wichita; Research Center
Investigational Oral Medication for RRMS

Kentucky

Lexington; Associates in Neurology, P.S.C.
A phase 3 study of Alemtuzumab infusion once a year vs. Rebif for patients with Relapsing Remitting multiple sclerosis who have not been on prior treatment.

Lexington; Research Center
Investigational Oral Medication for RRMS

Lexington; Associates in Neurology, P.S.C.
A phase 3 study of Alemtuzumab infusion once a year vs. Rebif for patients with Relapsing Remitting multiple sclerosis who have been on prior ABC treatment and have relapsed.

Lexington; Associates in Neurology, P.S.C.
A phase 3 trial comparing different doses of an oral study drug, BG00012,es vs placebo in subjects with relapsing remitting multiple sclerosis.

Lexington; Associates in Neurology, P.S.C.
A phase 3 trial of oral laguinimod taken once daily vs. placebo in subjects with relapsing remitting multiple sclerosis.

Lexington; Department of Neurology University of Kentucky College of Medicine
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Louisville; Research Center
Investigational Oral Medication for RRMS

Louisville; Kentucky Neuroscience Research
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Louisiana

New Orleans; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Shreveport; Research Center
Investigational Oral Medication for RRMS

Shreveport; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Maryland

Baltimore; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Baltimore; Research Center
Investigational Oral Medication for RRMS

Baltimore; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Baltimore; University of Maryland
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Greenbelt; Myron I. Murdock M.D. LLC
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Massachusetts

Bellingham; CNS Research of MA, Inc.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Boston; Research Center
Investigational Oral Medication for RRMS

Hopedale; Research Center
Investigational Oral Medication for RRMS

Lexington; Research Center
Investigational Oral Medication for RRMS

Springfield; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Worcester; Research Center
Investigational Oral Medication for RRMS

Michigan

Ann Arbor; Research Center
Investigational Oral Medication for RRMS

Clinton Township; Research Center
Investigational Oral Medication for RRMS

Farmington Hills; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Farmington Hills; Research Center
Investigational Oral Medication for RRMS

Farmington Hills; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Grand Rapids; Research Center
Investigational Oral Medication for RRMS

Grand Rapids; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Milwaukee; Center for Neurological Disorders
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Minnesota

Minneapolis; Research Center
Investigational Oral Medication for RRMS

Mississippi

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Missouri

Saint Louis; Research Center
Investigational Oral Medication for RRMS

Montana

Billings; Billings Clinic Research Center
Are you between the age of 18 and 65 with a diagnosis of Multiple Sclerosis?

Nevada

Las Vegas; Research Center
Investigational Oral Medication for RRMS

Las Vegas; University of Nevada School of Medicine
Research study in Relapsing-remitting Multiple Sclerosis (RRMS) - Oral investigational drug

Las Vegas; University of Nevada School of Medicine
Research study in Pseudobulbar Affect for individuals diagnosed with MS or ALS

Las Vegas; University of Nevada School of Medicine
Participants needed for a research study in Multiple Sclerosis

New Hampshire

Dover; Research Center
Investigational Oral Medication for RRMS

Lebanon; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lebanon; Research Center
Investigational Oral Medication for RRMS

Lebanon; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

New Jersey

Lawrenceville; AdvanceMed Research
The Dignity studies are phase III international multicenter, double-blind, randomized, placebo-controlled trials of botulinum toxin (BOTOX) in patients with spinal cord injury (SCI) or multiple sclerosis (MS); BOTOX is not yet licensed for these indications.

Sewell; Delaware Valley Urology, LLC
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Teaneck; Research Center
Investigational Oral Medication for RRMS

Teaneck; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Teaneck; Research Site [*]
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

West Orange; Associates in Urology
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

New Mexico

Albuquerque; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Albuquerque; Research Center
Investigational Oral Medication for RRMS

New York

Albany; Research Center
Investigational Oral Medication for RRMS

Albany; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Albany; Upstate Clinical Research, LLC
A Double-Blind, Placebo Controlled Multi-Center Study To Evaluate The Efficacy And Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

Amherst; Research Center
Investigational Oral Medication for RRMS

Amherst; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Buffalo; Research Center
Investigational Oral Medication for RRMS

Cedarhurst; Research Center
Investigational Oral Medication for RRMS

Columbus; Research Center
Investigational Oral Medication for RRMS

Garden City; Urology Institute of Long Island
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Mineola; Winthrop University Hospital Clinical Trials Center
Relapsing remitting multiple sclerosis

Mineola; Winthrop University Hospital Clinical Trials Center
Volunteers needed for a multiple sclerosis research study

New York; Biomedical Research Alliance of New York
Relapsing Remitting Multiple Sclerosis (RRMS)

New York; Mount Sinai Medical Center
A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis PROTOCOL: U2786g

New York; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New York; Research Center
Investigational Oral Medication for RRMS

New York; Mt. Sinai School of Medicine [*]
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

New York; Mount Sinai Medical Center
A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon beta 1-a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx Phase III)

New York; Mount Sinai Medical Center
ITN020AI: A Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patient with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS) (STAYCIS)

New York; Mount Sinai Medical Center
A 21 WEEK STUDY TO EVALUATE SAFETY AND EFFICACY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS.

New York; Mount Sinai Medical Center
OMEGA-Oral Megadose Corticosteroid Therapy of Acute Exacerbations in Multiple Sclerosis

New York; Mount Sinai Medical Center
A 24-month, double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of FTY720 1.25mg and 0.5mg administered once daily versus placebo in patients with relapsing remitting multiple sclerosis

New York; Mount Sinai Medical Center
The Establishment of a Patient Registry and Initiation of Related Projects of the New York State Multiple Sclerois Consortium

New York; Biomedical Research Alliance of New York
Relapsing - Remitting Multiple Sclerosis (RRMS)

New York; Biomedical Research Alliance of New York
Multiple Sclerosis treated with Betaseron� - Adults

New York; Biomedical Research Alliance of New York
Secondary Progressive Multiple Sclerosis - Adults

Patchogue; Research Center
Investigational Oral Medication for RRMS

Plainview; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Plainview; Research Center
Investigational Oral Medication for RRMS

Rochester; University of Rochester Medical Center
A research study for patients with symptoms of overactive bladder.

Schenectady; Schenectady Neurological Consultants, PC
The TYSABRI Global Observational Program in Safety (TYGRIS) is a safety observational cohort study designed to obtain long-term safety data in multiple sclerosis (MS) patients treated with TYSABRI in a clinical practice setting.

Staten Island; Research Center
Investigational Oral Medication for RRMS

Stony Brook; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Stony Brook; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Williamsville; Center for Urologic Research of WNY, LLC
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

North Carolina

Chapel Hill; UNC Chapel Hill/ UNC Hospital
A research study for patients with symptoms of overactive bladder

Charlotte; Research Center
Investigational Oral Medication for RRMS

Charlotte; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Charlotte; Research Center
Investigational Oral Medication for RRMS

Charlotte; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Raleigh; Research Center
Investigational Oral Medication for RRMS

Raleigh; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Salisbury; Central Carolina Neurology & Sleep, PA
Looking for MS Patients for a Quality of Life Study

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Winston Salem; Wake Forest University BMC
A research study for patients with symptoms of overactive bladder

Winston-Salem; Research Center
Investigational Oral Medication for RRMS

Winston-Salem; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Ohio

Akron; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Bellevue; Research Center
Investigational Oral Medication for RRMS

Cleveland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Cleveland; Research Center
Investigational Oral Medication for RRMS

Cleveland; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Columbus; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Columbus; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Columbus; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Dayton; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Oklahoma

Oklahoma City; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Oregon

Medford; Research Center
Investigational Oral Medication for RRMS

Portland; Research Center
Investigational Oral Medication for RRMS

Portland; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Portland; Oregon Health & Science University
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Tualatin; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Pennsylvania

Erie; Research Center
Investigational Oral Medication for RRMS

Hershey; Research Center
Investigational Oral Medication for RRMS

Lancaster; Urological Associates of Lancaster
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Philadelphia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Philadelphia; Research Center
Investigational Oral Medication for RRMS

Philadelphia; Thomas Jefferson University
A research study for patients with symptoms of overactive bladder

Philadelphia; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Pittsburg; Research Center
Investigational Oral Medication for RRMS

Pittsburgh; Research Center
Investigational Oral Medication for RRMS

Pittsburgh; University of Pittsburg Medical Center
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Rhode Island

East Providence; Research Center
Investigational Oral Medication for RRMS

Providence; CNS Research of RI, Inc.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Providence; Research Center
Investigational Oral Medication for RRMS

Providence; The Neurology Foundation,Inc.
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

South Carolina

Myrtle Beach; Carolina Urologic Research
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Tennessee

Cordova; Research Center
Investigational Oral Medication for RRMS

Franklin; Research Center
Investigational Oral Medication for RRMS

Franklin; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Germantown; The Conrad/ Pearson Clinic
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Knoxville; Research Center
Investigational Oral Medication for RRMS

Knoxville; Volunteer Research Group
A research study for patients with symptoms of overactive bladder

Memphis; Research Center
Investigational Oral Medication for RRMS

Nashville; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nashville; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nashville; Research Center
Investigational Oral Medication for RRMS

Various Cities; Research Center
FREEDOMS II - Multiple Sclerosis Study

Texas

Austin; Professional Quality Research Inc./ The Urology Team PA
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Dallas; Research Center
Investigational Oral Medication for RRMS

Dallas; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Galveston; Research Center
Investigational Oral Medication for RRMS

Houston; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Houston; Scott Dept of Urology/BCM
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Houston; Research Center
Investigational Oral Medication for RRMS

McAllen; Urology Associates of South Texas
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Round Rock; Research Center
Investigational Oral Medication for RRMS

San Antonio; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

San Antonio; Research Center
Investigational Oral Medication for RRMS

San Antonio; Urology San Antonio Research, PA
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Utah

Salt Lake City; Research Center
Investigational Oral Medication for RRMS

Vermont

Bennington; Research Center
Investigational Oral Medication for RRMS

Burlington; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Burlington; Research Center
Investigational Oral Medication for RRMS

Virginia

Alexandria; Adult & Pediatric Urologists
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Charlottesville; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Charlottesville; University of Virginia
UVa Department of Neurology seeks Men and Women ages 18-55 with Relapsing-Remitting Multiple Sclerosis for research study.

Newport News; Research Center
Investigational Oral Medication for RRMS

Richmond; Research Center
Investigational Oral Medication for RRMS

Richmond; McGuire Veterans Medical Center
A research study for patients with symptoms of overactive bladder

Richmond; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Roanoke; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Virginia Beach; Urology of Virginia
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Wien; Research Center
Investigational Oral Medication for RRMS

Washington

Kirkland; MS Center At Evergreen
A research study for patients with symptoms of overactive bladder.

Kirkland; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Kirkland; MS Center Evergreen
Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

Maitland; MS Center at Evergreen Healthcare
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Mountlake Terrace; Integrity Medical Research
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Mountlake Terrace; Integrity Medical Research, LLC
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Seattle; Research Center
Investigational Oral Medication for RRMS

Tacoma; Research Center
Investigational Oral Medication for RRMS

Tacoma; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Washington, DC

Washington; Research Center
Investigational Oral Medication for RRMS

Washington; Medical Faculty Associates, The George Washington University [*]
A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis

Washington; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Washington; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

West Virginia

Charleston; Research Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Charleston; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Wisconsin

Madison; Research Center
Investigational Oral Medication for RRMS

Milwaukee; Research Center
Investigational Oral Medication for RRMS

Milwaukee; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

International

Adelaide, SA, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Adelaide, SA, Australia; Royal Adelaide Hospital
A research study for patients with symptoms of overactive bladder.

Camperdown, NSW, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Chatswood, NSW, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Clayton, VIC, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Fitzroy, VIC, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Geelong, VIC, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Heidelberg, VIC, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Kogarah, NSW, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Liverpool, NSW, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Melbourne, VIC, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Newcastle, NSW, AUSTRALIA; Research Center
Investigational Oral Medication for RRMS

Graz, STYRIA, AUSTRIA; Research Center
Investigational Oral Medication for RRMS

Innsbruck, TYROL, AUSTRIA; Research Center
Investigational Oral Medication for RRMS

Linz, UPPER AUSTRIA, AUSTRIA; Research Center
Investigational Oral Medication for RRMS

Wien, VIENNA, AUSTRIA; Research Center
Investigational Oral Medication for RRMS

Gomel, HOMYELRSKAYA, BELARUS; Research Center
Investigational Oral Medication for RRMS

Minsk, MINSK, BELARUS; Research Center
Investigational Oral Medication for RRMS

Vitebsk, VITSYEBSKAYA, BELARUS; Research Center
Investigational Oral Medication for RRMS

Antwerpen, ANTWERPEN, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Brugge, WEST-VLAANDEREN, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Charleroi, HAINAUT, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Diepenbeek, LIMBURG, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Edegem, Belgium; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Leuven, FLEMISH BRABANT, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Li�ge, LIEGE, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Lommel, LIMBURG, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Overpelt, Belgium; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Sijsele-Damme, Belgium; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sijsele-Damme, WEST-VLAANDEREN, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Sijsele-Damme,WEST-VLAANDEREN, BELGIUM; Research Center
Investigational Oral Medication for RRMS

St. Truiden, Belgium; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Woluwe, BRUSSELS, BELGIUM; Research Center
Investigational Oral Medication for RRMS

Banja Luka, Republic Srpska, Bosnia; Research Center
Investigational Oral Medication for RRMS

Sarajevo, B&H Federation, Bosnia; Research Center
Investigational Oral Medication for RRMS

Tuzla, B&H Federation, Bosnia; Research Center
Investigational Oral Medication for RRMS

Campinas, SAO PAULO, BRAZIL; Research Center
Investigational Oral Medication for RRMS

Porto Alegre, RIO GRANDE DO SUL, BRAZIL; Research Center
Investigational Oral Medication for RRMS

S�o Paulo, SAO PAULO, BRAZIL; Research Center
Investigational Oral Medication for RRMS

Plovdiv, BULGARIA; Research Center
Investigational Oral Medication for RRMS

Rousse, BULGARIA; Research Center
Investigational Oral Medication for RRMS

Sofia, BULGARIA; Research Center
Investigational Oral Medication for RRMS

Sofia, Bulgaria; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sofia, BULGARIA; Research Center
Investigational Oral Medication for RRMS

Stara Zagora, BULGARIA; Research Center
Investigational Oral Medication for RRMS

Varna, BULGARIA; Research Center
Investigational Oral Medication for RRMS

Burnaby, BC, CANADA; Research Center
Investigational Oral Medication for RRMS

Edmonton, AB, Canada; Research Center
Investigational Oral Medication for RRMS

Gatineau, QC, CANADA; Research Center
Investigational Oral Medication for RRMS

Halifax, NS, CANADA; Research Center
Investigational Oral Medication for RRMS

Levis, PQ, CANADA; Research Center
Investigational Oral Medication for RRMS

Montreal, QC, CANADA; Research Center
Investigational Oral Medication for RRMS

Montreal, QC, Canada; Research Center
Investigational Oral Medication for RRMS

Ottawa, ON, CANADA; Research Center
Investigational Oral Medication for RRMS

Quebec, QC, CANADA; Research Center
Investigational Oral Medication for RRMS

Regina, SK, CANADA; Research Center
Investigational Oral Medication for RRMS

Sherbrooke, QC, CANADA; Research Center
Investigational Oral Medication for RRMS

Toronto, ON, Canada; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vancouver, BC, Canada; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Victoria, BC, Canada; Can-Med Clinical Research Inc.
A research study for patients with symptoms of overactive bladder

Victoria, BC, Canada; Dr. Steinhoff Clinical Research
A research study for patients with symptoms of overactive bladder.

San Jos�, San Jos�, COSTA RICA; Research Center
Investigational Oral Medication for RRMS

Osijek, Osijek-Baranja, CROATIA; Research Center
Investigational Oral Medication for RRMS

Rijeka, Primorje-Gorski Kotar, CROATIA; Research Center
Investigational Oral Medication for RRMS

Zagreb, CROATIA; Research Center
Investigational Oral Medication for RRMS

Brno, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Jihlava, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Opava, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Ostrava, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ostrava, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Ostrava, North Moravia, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Ostrava-Moravska Ostrava, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Pardubice, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Plzen, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Prague, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Praha, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Praha 2, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Praha 5, PRAHA, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Teplice, CZECH REPUBLIC; Research Center
Investigational Oral Medication for RRMS

Teplice, Czech Republic; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Arhus, Denmark; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kuressaare, ESTONIA; Research Center
Investigational Oral Medication for RRMS

Parnu, ESTONIA; Research Center
Investigational Oral Medication for RRMS

Tallinn, ESTONIA; Research Center
Investigational Oral Medication for RRMS

Tartu, ESTONIA; Research Center
Investigational Oral Medication for RRMS

Helsinki, Finland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Turku, Finland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bobigny, FRANCE; Research Center
Investigational Oral Medication for RRMS

Bordeaux, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bordeaux, FRANCE; Research Center
Investigational Oral Medication for RRMS

Caen cedex, FRANCE; Research Center
Investigational Oral Medication for RRMS

Caen Cedex 9, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Clermont Ferrand, FRANCE; Research Center
Investigational Oral Medication for RRMS

Clermont-Ferrand Cedex1, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Dijon, FRANCE; Research Center
Investigational Oral Medication for RRMS

Lille cedex, FRANCE; Research Center
Investigational Oral Medication for RRMS

Lyon, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lyon cedex 03, FRANCE; Research Center
Investigational Oral Medication for RRMS

Marseille Cedex 9, FRANCE; Research Center
Investigational Oral Medication for RRMS

Montpellier, FRANCE; Research Center
Investigational Oral Medication for RRMS

Montpellier Cedex, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Montpellier cedex 5, FRANCE; Research Center
Investigational Oral Medication for RRMS

Nancy cedex, FRANCE; Research Center
Investigational Oral Medication for RRMS

Nice, FRANCE; Research Center
Investigational Oral Medication for RRMS

Nimes, France; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

N�mes, FRANCE; Research Center
Investigational Oral Medication for RRMS

Paris, FRANCE; Research Center
Investigational Oral Medication for RRMS

Rennes, FRANCE; Research Center
Investigational Oral Medication for RRMS

Strasbourg, ALSACE, FRANCE; Research Center
Investigational Oral Medication for RRMS

Bad Neustadt/Saale, BAYERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Bamberg, BAYERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Bayreuth, BAYERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Berg, Starnberger See, GERMANY; Research Center
Investigational Oral Medication for RRMS

Berlin, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Berlin, Germany; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Berlin BERLIN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Berlin, BERLIN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Bochum, NORDRHEIN-WESTFALEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

D�sseldorf, NORDRHEIN-WESTFALEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Erbach, GERMANY; Research Center
Investigational Oral Medication for RRMS

Erlangen, BAYERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Essen, NORDRHEIN-WESTFALEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Gie�en, HESSEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Halle (Saale), SACHSEN-ANHALT, GERMANY; Research Center
Investigational Oral Medication for RRMS

Hamburg, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Hamburg, HAMBURG, GERMANY; Research Center
Investigational Oral Medication for RRMS

Hanburg, GERMANY; Research Center
Investigational Oral Medication for RRMS

Hannover, NIEDERSACHSEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Heidelberg, BADEN-WUTTEMBERG, GERMANY; Research Center
Investigational Oral Medication for RRMS

Jena, THURINGEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

K�ln, NORDRHEIN-WESTFALEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Leipzig, SACHSEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Lengerich, GERMANY; Research Center
Investigational Oral Medication for RRMS

Magdeburg, SACHSEN-ANHALT, GERMANY; Research Center
Investigational Oral Medication for RRMS

Marburg, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Marburg, HESSEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Minden, NORDRHEIN-WESTFALEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

M�nchen, BAYERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

M�nster, NORDRHEIN-WESTFALEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Osnabr�ck, NIEDERSACHSEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Regensburg, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Regensburg, BAYERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Schwerin, MECKLENBURG-VORPOMMERN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Siegen, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

T�bingen, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ulm, Germany; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Westerstede, NIEDERSACHSEN, GERMANY; Research Center
Investigational Oral Medication for RRMS

Athens, ATTICA, GREECE; Research Center
Investigational Oral Medication for RRMS

Guatemala, GREECE; Research Center
Investigational Oral Medication for RRMS

Guatemala City, GREECE; Research Center
Investigational Oral Medication for RRMS

Heraklion, GREECE; Research Center
Investigational Oral Medication for RRMS

Ioannina, GREECE; Research Center
Investigational Oral Medication for RRMS

Patras, GREECE; Research Center
Investigational Oral Medication for RRMS

Thessaloniki, GREECE; Research Center
Investigational Oral Medication for RRMS

Budapest, Hungary; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Gyor, Hungary; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Bangalore, INDIA; Research Center
Investigational Oral Medication for RRMS

Chandigarh, INDIA; Research Center
Investigational Oral Medication for RRMS

Chennai, INDIA; Research Center
Investigational Oral Medication for RRMS

Coimbatore, INDIA; Research Center
Investigational Oral Medication for RRMS

Delhi, INDIA; Research Center
Investigational Oral Medication for RRMS

Hyderabad, INDIA; Research Center
Investigational Oral Medication for RRMS

Jaipur, INDIA; Research Center
Investigational Oral Medication for RRMS

Kolkata, INDIA; Research Center
Investigational Oral Medication for RRMS

Lucknow, INDIA; Research Center
Investigational Oral Medication for RRMS

Mangalore, INDIA; Research Center
Investigational Oral Medication for RRMS

Mumbai, INDIA; Research Center
Investigational Oral Medication for RRMS

New Dehli, INDIA; Research Center
Investigational Oral Medication for RRMS

New Delhi, INDIA; Research Center
Investigational Oral Medication for RRMS

Pune, INDIA; Research Center
Investigational Oral Medication for RRMS

Cork, Cork, IRELAND; Research Center
Investigational Oral Medication for RRMS

Dublin, IRELAND; Research Center
Investigational Oral Medication for RRMS

Ashkelon, ISRAEL; Research Center
Investigational Oral Medication for RRMS

Beer Yaakov, ISRAEL; Research Center
Investigational Oral Medication for RRMS

Holon, ISRAEL; Research Center
Investigational Oral Medication for RRMS

Jerusalem, ISRAEL; Research Center
Investigational Oral Medication for RRMS

Safed, ISRAEL; Research Center
Investigational Oral Medication for RRMS

Tel Hashomer, ISRAEL; Research Center
Investigational Oral Medication for RRMS

Milan, Italy; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Roma, Italy; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Roma, ITALY; Research Center
Investigational Oral Medication for RRMS

Almata, KAZAKHSTAN; Research Center
Investigational Oral Medication for RRMS

Almaty, KAZAKHSTAN; Research Center
Investigational Oral Medication for RRMS

Astana, KAZAKHSTAN; Research Center
Investigational Oral Medication for RRMS

Karaganda, KAZAKHSTAN; Research Center
Investigational Oral Medication for RRMS

Symkent, KAZAKHSTAN; Research Center
Investigational Oral Medication for RRMS

Riga, LATVIA; Research Center
Investigational Oral Medication for RRMS

Skopje, Macedonia; Research Center
Investigational Oral Medication for RRMS

Aguascalientes, Mexico; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Aguascalientes, Aguascalientes, MEXICO; Research Center
Investigational Oral Medication for RRMS

Chihuahua, Mexico; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Chihuahua, MEXICO; Research Center
Investigational Oral Medication for RRMS

Chihuahua, Chih, MEXICO; Research Center
Investigational Oral Medication for RRMS

Guadalajara, Jal, MEXICO; Research Center
Investigational Oral Medication for RRMS

Guadalajara, JALISCO, MEXICO; Research Center
Investigational Oral Medication for RRMS

Merida, Yuc, MEXICO; Research Center
Investigational Oral Medication for RRMS

Mexico D.F, MEXICO; Research Center
Investigational Oral Medication for RRMS

Mexico, 14000, MEXICO; Research Center
Investigational Oral Medication for RRMS

Mexico, DISTRITO FEDERAL, MEXICO; Research Center
Investigational Oral Medication for RRMS

Monterrey, NL, MEXICO; Research Center
Investigational Oral Medication for RRMS

Monterrey, NUEVO LEON, MEXICO; Research Center
Investigational Oral Medication for RRMS

Morelia, Michoacan, MEXICO; Research Center
Investigational Oral Medication for RRMS

Puebla, PUEBLA, MEXICO; Research Center
Investigational Oral Medication for RRMS

San Luis Potosi, SAN LUIS POTOSI, MEXICO; Research Center
Investigational Oral Medication for RRMS

Tijuana,Baja California, MEXICO; Research Center
Investigational Oral Medication for RRMS

Chisinau, MOLDOVA; Research Center
Investigational Oral Medication for RRMS

Breda, Netherlands; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Breda, Netherlands; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Breda, NOORD-BRABANT, NETHERLANDS; Research Center
Investigational Oral Medication for RRMS

Nieuwegein, Netherlands; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nijmegen, Netherlands; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Sittard, LIMBURG, NETHERLANDS; Research Center
Investigational Oral Medication for RRMS

Christchurch, NEW ZEALAND; Research Center
Investigational Oral Medication for RRMS

Grafton, Auckland, NEW ZEALAND; Research Center
Investigational Oral Medication for RRMS

Hamilton, NEW ZEALAND; Research Center
Investigational Oral Medication for RRMS

Bialystok, PODLASKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Bydgoszcz, KUJAWSKO-POMORSKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Gdansk, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Gdansk, POMORSKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Katowice, SLASKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Krak�w, MALOPOLSKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Lodz, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

L�dz, LODZKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Lublin, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lublin, DOLNOSLASKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Poznan, WIELKOPOLSKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Sosnowiec, SLASKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Szczecin, POLAND; Research Center
Investigational Oral Medication for RRMS

Warszawa, Poland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Warszawa, MAZOWIECKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Wroclaw, DOLNOSLASKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Zabrze, SLASKIE, POLAND; Research Center
Investigational Oral Medication for RRMS

Guaynabo, PUERTO RICO; Research Center
Investigational Oral Medication for RRMS

Guaynabo, Puerto Rico; Research Site
New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis

Bucresti, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Bucuresti, Romania; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bucuresti, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Cluj-Napoca, Cluj, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Iasi, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Oradea, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Targu Mures, Romania; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Timisoara, Timis, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Tirgu Mures, ROMANIA; Research Center
Investigational Oral Medication for RRMS

Ekaterinburg, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kazan, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Moscow, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nizhny Novgorod, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Novosibirsk, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Tyumen, Russian Federation; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Belgrade, SERBIA; Research Center
Investigational Oral Medication for RRMS

Kragujevac, SERBIA; Research Center
Investigational Oral Medication for RRMS

Nis, SERBIA; Research Center
Investigational Oral Medication for RRMS

Novi Sad, SERBIA; Research Center
Investigational Oral Medication for RRMS

Banska Bystrica, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bratislava, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bratislava, SLOVAKIA; Research Center
Investigational Oral Medication for RRMS

Kosice, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kosice, SLOVAKIA; Research Center
Investigational Oral Medication for RRMS

Martin, Zilina, SLOVAKIA; Research Center
Investigational Oral Medication for RRMS

Nitra, Slovakia; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ruzomberok, SLOVAKIA; Research Center
Investigational Oral Medication for RRMS

Cape Town, Western Cape, SOUTH AFRICA; Research Center
Investigational Oral Medication for RRMS

Durban, KwaZulu-Natal, SOUTH AFRICA; Research Center
Investigational Oral Medication for RRMS

Parow, Western Cape, SOUTH AFRICA; Research Center
Investigational Oral Medication for RRMS

Rosebank, SOUTH AFRICA; Research Center
Investigational Oral Medication for RRMS

Barcelona, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Barcelona, BARCELONA, SPAIN; Research Center
Investigational Oral Medication for RRMS

C�rdoba, CORDOBA, SPAIN; Research Center
Investigational Oral Medication for RRMS

Madrid, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Madrid, MADRID, SPAIN; Research Center
Investigational Oral Medication for RRMS

Malaga, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

M�laga, MALAGA, SPAIN; Research Center
Investigational Oral Medication for RRMS

Oviedo, Spain; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Santiago de Compostela, LA CORUNA, SPAIN; Research Center
Investigational Oral Medication for RRMS

Sevilla, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sevilla, ANDALUC�A, SPAIN; Research Center
Investigational Oral Medication for RRMS

Valencia, Spain; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Basel, Switzerland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Basel, BASEL, SWITZERLAND; Research Center
Investigational Oral Medication for RRMS

Lausanne, Switzerland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sankt Gallen, SANKT GALLEN, SWITZERLAND; Research Center
Investigational Oral Medication for RRMS

Zurich, Switzerland; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Z�rich, ZURICH, SWITZERLAND; Research Center
Investigational Oral Medication for RRMS

Adana, ADANA, TURKEY; Research Center
Investigational Oral Medication for RRMS

Istanbul, TURKEY; Research Center
Investigational Oral Medication for RRMS

Izmir, TURKEY; Research Center
Investigational Oral Medication for RRMS

Trabzon, TURKEY; Research Center
Investigational Oral Medication for RRMS

Kharkiv, KHARKIV, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Kharkov, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kiev, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kyiv, KIEV, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Lviv, LVIV, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Odessa, ODESSA, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Poltava, POLTAVA, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Propetrovsk, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Simferopol, CRIMEA, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Vinnitsa, VINNYTSYA, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Vinnytsya, Ukraine; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Zaporozhye, ZAPORIZHZHYA, UKRAINE; Research Center
Investigational Oral Medication for RRMS

Croydon, Surrey, United Kingdom; UCB Clinical Trial Call Center
Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.

Liverpool, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

London, ENGLAND, UNITED KINGDOM; Research Center
Investigational Oral Medication for RRMS

Newcastle, United Kingdom; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Newcastle upon Tyne, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Newcastle upon Tyne, ENGLAND, UNITED KINGDOM; Research Center
Investigational Oral Medication for RRMS

Nottingham, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Oxford, ENGLAND, UNITED KINGDOM; Research Center
Investigational Oral Medication for RRMS

Sheffield, United Kingdom; Research Site:
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sheffield, United Kingdom; UCB Clinical Trial Call Center
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Sheffield, ENGLAND, UNITED KINGDOM; Research Center
Investigational Oral Medication for RRMS

Staffordshire, ENGLAND, UNITED KINGDOM; Research Center
Investigational Oral Medication for RRMS

Tooting, London, United Kingdom; UCB Clinical Trial Call Center
Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Patient Resources: [ Trial Listing ] [ Notification Services ] [ Drug Directories ]
[ About Clinical Research ] [ Patient Resources ] [ Patient Bookstore ]
Professional Resources: [ Research Center Profiles ] [ Industry Provider Profiles ] [ Jobs in Clinical Research ]
[ Industry News ] [ Professional Resources ] [ Professional Bookstore ]
General: [ Search ] [ Site Map ] [ Your Privacy ] [ CW World ] [ Home ]